

1 Case fatality risk by age from COVID-19 in a high testing 2 setting in Latin America: Chile, March-May, 2020

3 Running title: COVID19 case fatality risk by age, Chile

4 Authors:

5 Eduardo A. Undurraga^{1,2*}, Gerardo Chowell³, Kenji Mizumoto^{4,5}

6
7

8 Affiliations:

9 ¹ Escuela de Gobierno, Pontificia Universidad Católica de Chile, Santiago, Región
10 Metropolitana, Chile

11 ² Millennium Initiative for Collaborative Research in Bacterial Resistance (MICROB-R),
12 Chile

13 ³ Department of Population Health Sciences, School of Public Health, Georgia State
14 University, Atlanta, Georgia, USA

15 ⁴ Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University
16 Yoshida-Nakaadachi-cho, Sakyo-ku, Kyoto, Japan

17 ⁵ Hakubi Center for Advanced Research, Kyoto University, Yoshidahonmachi, Sakyo-
18 ku, Kyoto, Japan;

19

20 Word count:

21 Abstract: 200/200

22 Main: 2173/3500

23 References: 50/50

24 Tables and Figures: 6/7 (max 4 panels per figure)

25

26

27

28 ***Address for correspondence:** Eduardo A. Undurraga, Escuela de Gobierno, Pontificia Universidad Católica
29 de Chile. Vicuña Mackenna 4860, Macul CP 7820436, Región Metropolitana, Chile; email: eundurra@uc.cl;

30 phone: +56 (2) 2354 9536. ORCID: 0000-0002-4425-1253

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 **Background**

33 Early severity estimates of COVID-19 are critically needed to better assess the potential impact
34 of the ongoing pandemic in different socio-demographic groups. Using real-time
35 epidemiological data from Chile, the nation in Latin America with the highest testing rate for
36 COVID-19, we derive delay-adjusted severity estimates by age group as of May 18th, 2020.

37 **Methods**

38 We employed statistical methods and daily series of age-stratified COVID-19 cases and deaths
39 reported in Chile to estimate the delay-adjusted case fatality rate across six age groups.

40 **Results**

41 Our most recent estimates of the time-delay adjusted case fatality rate are 0.08% (95% Credible
42 Interval CrI:0.04-0.13%) among persons aged 0-39, 0.61% (95%CrI:0.41-0.87%) for those
43 aged 40-49, 1.06% (95%CrI:0.76-1.40%) for those aged 50-59, 3.79% (95%CrI:3.04-4.66%)
44 for those aged 60-69, 12.22% (95%CrI:10.40-14.38%) for those aged 70-79, and 26.27%
45 (95%CrI:22.95-2980%) for persons aged 80 and over. The overall time-delay adjusted case
46 fatality rate is 1.78% (95%CrI: 1.63-1.95%) across all age groups.

47 **Conclusions**

48 Severity estimates from COVID-19 in Chile indicate a disproportionate impact among seniors,
49 especially among those aged ≥ 70 years. COVID-19 is imposing a high death toll in Latin
50 America. Case fatality rates in Chile suggest the health system is not yet overwhelmed, but the
51 epidemic is expanding fast.

52

53 **Keywords:** COVID-19, Chile, death risk by age group, time-delay adjusted CFR, 2020

54

55

56 **Background**

57 The coronavirus disease 2019 (CoVID-19) pandemic has strained or overwhelmed health
58 systems across the world [1, 2], with almost five million lab-confirmed cases and 320
59 thousand deaths as of May 18, 2020 [3, 4]. The first case in Latin America of Severe Acute
60 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of CoVID-19, was reported
61 in February 25 in São Paulo, Brazil, a travel hub in the region [5]. A few weeks later,
62 countries in the region had imposed major epidemic control measures, such as closed borders,
63 restricted travel, closure of schools and universities, and enforced lockdowns [6]. Despite
64 these measures, the ongoing coronavirus pandemic has already imposed a high toll to most
65 countries in Latin America, killing thousands in Brazil (21,408), Ecuador (3,056), and Peru
66 (3,244) thus far [3]. In addition to already strained healthcare systems, other factors have
67 affected the dynamic of the pandemic in the region, including migration, sociopolitical crises,
68 struggling economies, other infectious disease outbreaks, and challenges tied to the
69 implementation of social distancing, hygiene, and lockdown strategies, due to inadequate
70 water and sanitation infrastructure, precarious living conditions [6-11].

71
72 Chile has seen a rapid increase in CoVID-19 cases in recent weeks, with 46,048 cases and
73 544 deaths [12] as of May 18, 2020. The first CoVID-19 case in Chile was reported in March
74 3, 2020 [12]. The Ministry of Health put in place a quick response effort, announcing
75 restrictions on large gatherings in March 13th, and subsequently, closing all daycares, schools,
76 and universities (March 16th), imposing border controls and telework recommendations
77 (March 18th), closing non-essential businesses (March 19th), national night curfews (March
78 22nd), and implementing a strategy of intermittent lockdowns in selected municipalities since
79 March 22nd [13-15]. Estimates for the early stage of the epidemic showed sustained
80 transmission with an estimated reproduction number $R \sim 1.6$ (95% CI: 1.5, 1.7), and 20-day

81 ahead forecast suggested containment measures significantly slowed down the spread of the
82 virus [16]. The crude case fatality rate (CFR), the number of cumulative deaths over the
83 number of cumulative cases, in Chile (1.2%) has remained well below the global average
84 (6.5%) [4, 12]. But in light of limited health system capacity, infectious disease experts have
85 warned about authorities' excessive confidence over early successes [17]. In fact, models
86 have estimated the number of ill patients could overwhelm treatment capacity late May to
87 mid-June [18], which has not yet occurred.

88

89 SARS-CoV-2 infection can result in a wide spectrum of clinical outcomes, including
90 asymptomatic infection, mild symptoms, hospitalization, or death [19-21]. The case fatality
91 rate (CFR) is a commonly used estimate of the severity of an epidemic [22], as it provides a
92 reliable benchmark for public health officials to make decisions about intensity and duration
93 of interventions to mitigate or suppress an epidemic [23]. But obtaining CFR estimates
94 during the course of an epidemic is challenging, as CFR is typically affected by right
95 censoring and ascertainment bias [24-28]. Right-censoring occurs because of a time delay
96 between onset of symptoms and death and may lead to underestimation of CFR; under
97 ascertainment of cases occurs because mild or asymptomatic COVID-19 cases often go
98 undetected by disease surveillance systems, which are not designed to detect all infections
99 [25, 29-31].

100

101 Here we provide real-time estimates of adjusted age-specific CFR during the CoVID-19
102 epidemic in Chile, March through May 2020, to gauge the severity of the SARS-CoV-2
103 epidemic. In particular, Chile has tested at a higher rate (23.13 total tests per 1000 people by
104 May 22) than any other country in Latin America [32, 33]. The health system has not yet
105 reached its maximum capacity, with 85% and 96% of critical beds in use nationally and in the

106 capital Santiago [34], respectively, so our estimates are still not affected by excess deaths due
 107 to healthcare demand exceeding capacity. To our knowledge, these are the first estimates of
 108 CFR in Latin America, which could inform critical decisions by public health officials.

109

110 **Methods**

111 **Data Sources**

112 We obtained daily cumulative numbers of reported laboratory confirmed COVID-19 cases
 113 and deaths stratified by age group from March 3, 2020, through May 18, 2020, from the
 114 Ministry of Health [12]. Data on deaths by age group were missing for a few days (March 29
 115 and 31, April 1-3, 6, 8).

116

117 **Statistical analysis**

118 For the estimation of CFR in real time, we employed the delay from hospitalization to death,
 119 h_s , which is assumed to be given by $h_s = H(s) - H(s-1)$ for $s > 0$ where $H(s)$ is a cumulative
 120 density function of the delay from hospitalization to death and follows a gamma distribution
 121 with mean 10.1 days and standard deviation (SD) 5.4 days [35]. Let π_{a,t_i} be the time-delay
 122 adjusted case fatality ratio on reported day t_i in area a , the likelihood function of the estimate

123 π_{a,t_i} is

124 $L(\pi_{a,t_i}; c_{a,t}, D_{a,t})$

$$\begin{aligned}
 &= \prod_{t_i} \left(\frac{\sum_{t=1}^{t_i} c_{a,t}}{D_{a,t_i}} \right) \left(\pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{D_{a,t_i}} \left(1 \right. \\
 &\quad \left. - \pi_{a,t_i} \frac{\sum_{t=2}^{t_i} \sum_{s=1}^{t-1} c_{a,t-s} h_s}{\sum_{t=1}^{t_i} c_{a,t}} \right)^{\sum_{t=1}^{t_i} c_{a,t} - D_{a,t_i}}
 \end{aligned}$$

126

127 where $c_{a,t}$ represents the number of new cases with reported day t in area a , and D_{a,t_i} is the
128 cumulative number of deaths until reported day t_i in area a [36, 37]. Among the cumulative
129 cases with reported day t in area a , D_{a,t_i} have died and the remainder have survived the
130 infection. The contribution of those who have died with biased death risk is shown in the
131 middle parenthetical term and the contribution of survivors is presented in the right
132 parenthetical term. We assume that D_{a,t_i} is the result of the binomial sampling process with
133 probability π_{a,t_i} .

134

135 We estimated model parameters using a Monte Carlo Markov Chain (MCMC) method in a
136 Bayesian framework. Convergence of MCMC chains were evaluated using the potential scale
137 reduction statistic [38, 39]. Estimates and 95% credibility intervals (CrI) for these estimates
138 are based on the posterior probability distribution of each parameter and based on the
139 samples drawn from the posterior distributions. All statistical analyses were conducted in R
140 version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) using the ‘rstan’
141 package.

142

143 **Results**

144 As of May 18, a total of 46,048 COVID-19 cases and 544 deaths have been reported in Chile.
145 Reported cases were mostly observed among persons aged 0-39 years (53.9%), followed by
146 40-49 year olds (17.3%), and 50-59 year olds (14.4%) (Table 1). Most reported deaths
147 correspond to seniors, especially those aged 80 years and older (38.1%), followed 70-79 year
148 olds (27.9%), and 60-69 year olds (16.9%) (Table 1).

149

150 Figure 1A presents the gender proportion of reported cases by age groups and cumulative
151 morbidity ratio by gender and age group. Across age groups, the proportion of male cases is

152 higher than 50%, except for those aged 80 years and above (χ^2 test, p-value <0.0001).

153 Cumulative morbidity ratio by gender and age group is presented in Figure 1B, indicating
154 that ratio among males is higher than among females across age groups (proportion test, p-
155 value < 0.000) except for those aged 80 years and above (proportion test, p-value = 0.13).

156

157 Figure 2 displays the cumulative cases of CoVID-19 by age group (A through G), and the
158 cumulative deaths by age group (H through N) over time. The figure suggests cumulative
159 cases of CoVID-19 are growing faster than cumulative deaths. The growth curve for
160 cumulative cases across all age groups and for persons aged 0-39 appears to increase
161 exponentially after around day 30 (April 30th, 2020), while exponential growth in cumulative
162 deaths for all age groups appears to occur after day 45 (May 15th, 2020).

163

164 Figure 3 shows observed and model-based posterior estimates of the crude CFR of CoVID-19
165 by age group (A-G) and time-delay adjusted CFR by age group (H-N). Black dots show
166 crude case fatality ratios, and light and dark indicate 95% and 50% credible intervals for
167 posterior estimates, respectively.

168

169 Overall, our model-based crude CFR fitted the observed data well. Crude CFR for all age
170 groups (G) increased at an early stage of the epidemic, peaking around April 25th and was
171 followed by a decrease in CFR for about two weeks. There is a suggestive increasing trend
172 across most age groups starting around May 10th, 2020. Our model-based posterior estimates
173 for the time-delay adjusted CFR are substantially higher than the crude observed CFR. The
174 overall adjusted CFR follows a decreasing trend, except for infected patients aged 50-59
175 years, where the adjusted CFR increases until around April 21st.

176

177 The most recent estimates (May 18, 2020) of the time-delay adjusted CFR are 0.08% (95%
178 CrI: 0.04-0.13%) for persons aged 0-39, 0.61% (95%CrI: 0.41-0.87%) for those aged 40-49,
179 1.06% (95%CrI: 0.76-1.40%) for those aged 50-59, 3.79% (95%CrI: 3.04-4.66%) for those
180 aged 60-69, 12.22% (95%CrI: 10.40-14.38%) for those aged 70-79, and 26.27% (95%CrI:
181 22.95-2980%) for persons aged 80 and over. The overall time-delay adjusted CFR is 1.78%
182 (95%CrI: 1.63-1.95%) across all age groups (Table 2, Figure 4).

183

184 **Discussion**

185 To the best of our knowledge, this is the first study to estimate the time delay adjusted CFR
186 by age group for COVID-19 in Latin America, a region that has yet received little attention
187 during the ongoing coronavirus pandemic. Consistent with other recent COVID-19 research
188 [23, 25, 40], our results show the COVID-19 epidemic in Chile disproportionately influenced
189 seniors, especially those aged ≥ 70 years. These results suggest that an aging population
190 could exacerbate the fatality impact of COVID-19 [41], similar to influenza and respiratory
191 syncytial virus [42], and consistent with data available from Italy[41]. The comparatively low
192 CFR observed in Chile during the early stages of the epidemic [17], probably reflected the
193 age structure and socioeconomic status of initial cases. During the first weeks of the
194 pandemic, COVID-19 cases occurred among relatively young age groups, with most
195 transmission occurring among individuals between 20 and 60 years of age, and in high-
196 income communities with better access to healthcare and lower prevalence of risk factors for
197 severe COVID-19 [12, 43, 44].

198

199 Our latest estimates (as of May 18th, 2020) of the adjusted CFR among those aged 80 and
200 over reach values as high as 26.3% (95%CrI: 23.0-29.8), an estimate that is 328-fold higher

201 than our estimates for those aged 0-39 (0.08%), and 2.2-fold higher than our estimates for
202 those aged 70-79 (12.2%).

203

204 An upward trend in the crude CFR, as seen for the overall population through most of April
205 and particularly for the 50-59 age group, suggests the transmission is spreading to more
206 vulnerable populations. Interestingly, throughout March, most of transmission occurred
207 among relatively young, better-off populations. In Santiago, which has more than 75% of
208 COVID-19 cases in Chile, targeted enforced quarantines were put in place starting March
209 28th through mid-April in seven municipalities, six of which are among the richest in Chile
210 [45]. Epidemic transmission thus moved during April towards lower income municipalities,
211 where social distancing measures are more challenging to comply with, due to a higher
212 proportion of the population participating in the informal economy, higher population
213 density, poorer infrastructure, and lower quality healthcare [12, 46]. An upward trend in the
214 crude CFR could also result from an increasing number of unreported cases due to saturated
215 testing capacity. However, this is an unlikely explanation as RT-PCR testing capacity has
216 increased with cases, maintaining an average positivity rate (positive tests / total tests) of
217 9.7% throughout April (SD: 2.4%). However, results show an increase in crude CFR around
218 day 45 (May 15th, 2020), probably reflecting the exponential increase of cumulative cases
219 around day 30 (April 30, 2020), and a substantial increase in positive test rate (average in
220 May 1-18: 15.2% SD:4.5), which suggests there is probably an increasing proportion of
221 under diagnosed COVID-19 cases in Chile [47].

222

223 The downward trend in the adjusted CFR at the early stage of the study period may have been
224 influenced by reporting delays. In particular, the observed differences in our estimates of the

225 crude and adjusted CFR are directly due to the time-delay which we assume fixed during the
226 course of the epidemic.

227

228 The small proportion of men (38.8%) among CoVID-19 cases in people aged 80 and over is
229 probably attributable to the relatively small male population size for that age group; men
230 represent only 37% of the population >80 in Chile [48]. Higher mortality among men has
231 been reported in China and the U.S. [49, 50], our data provide the opportunity to examine the
232 CFR by gender and age.

233

234 Our study is not exempted from limitations. Our CFR estimates are probably affected by
235 under ascertainment, as has been estimated elsewhere [24-28], which may have pushed our
236 estimates upwards. Infectious disease with a substantial share of asymptomatic or mild
237 infections, such as COVID-19, may be more accurately characterized by infection-fatality
238 risk (deaths / infected people), but those data are not yet available in Chile.

239

240 In conclusion, using real-time epidemiological data from a high COVID-19 testing setting in
241 Latin America, we found that COVID-19 epidemic in Chile disproportionately affected
242 seniors, especially those aged ≥ 70 years, suggesting an older population could exacerbate the
243 death toll brought by COVID-19. COVID-19 is already imposing a high death toll in Latin
244 America. Case fatality rates in Chile suggest the health system is not yet overwhelmed, but
245 the epidemic is expanding fast, and healthcare demand may soon exceed capacity. These real-
246 time estimates may help inform decisions by public health officials in the region, and
247 underscore the need for continuous efforts to face this pandemic.

248

249

250 **Acknowledgments**

251 This work was supported by the Japan Society for the Promotion of Science (JSPS)
252 KAKENHI “[grant Number 20H03940]”; the Leading Initiative for Excellent Young
253 Researchers from the Ministry of Education, Culture, Sport, Science & Technology of Japan
254 to [KM]; National Science Foundation NSF “[grant 1414374]” as part of the joint NSF-
255 National Institutes of Health NIH-United States Department of Agriculture USDA Ecology
256 and Evolution of Infectious Diseases program; UK Biotechnology and Biological Sciences
257 Research Council “[grant BB/M008894/1]” to [GC]; and the Millennium Science Initiative of
258 the Ministry of Economy, Development, and Tourism, Government of Chile, “[grant
259 Millennium Initiative for Collaborative Research in Bacterial Resistance]”.

260

261 **Conflict of interest**

262 All authors report no conflicts of interest.

263

264

265 **References**

266 1. Walker PG, Whittaker C, Watson O, et al. The Global Impact of COVID-19 and Strategies
267 for Mitigation and Suppression. On behalf of the imperial college covid-19 response team,
268 Imperial College of London **2020**.

269 2. Flaxman S, Mishra S, Gandy A. Estimating the number of infections and the impact of
270 non-pharmaceutical interventions on COVID-19 in 11 European countries. Imperial College
271 COVID-19 Response Team **2020**; 30.

272 3. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real
273 time. *Lancet Infect Dis* **2020**; 20:P533-P4.

- 274 4. World Health Organization. Coronavirus Disease (COVID-19) Outbreak. Available from:
275 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019>. Accessed 20 May 2020.
- 276 5. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-19 in Latin
277 America: The implications of the first confirmed case in Brazil. *Travel Med Infect Dis* **2020**;
278 epub ahead of print:101613.
- 279 6. Burki T. COVID-19 in Latin America. *Lancet Infect Dis* **2020**; 20:547-8.
- 280 7. The Lancet. The unfolding migrant crisis in Latin America. *Lancet* **2019**; 394:1966.
- 281 8. Fetzer TR, Witte M, Hensel L, et al. Global Behaviors and Perceptions at the Onset of the
282 COVID-19 Pandemic. National Bureau of Economic Research Working Paper Series **2020**;
283 No. 27082.
- 284 9. Navarro J-C, Arrivillaga-Henríquez J, Salazar-Loor J, Rodriguez-Morales AJ. COVID-19
285 and dengue, co-epidemics in Ecuador and other countries in Latin America: Pushing strained
286 health care systems over the edge. *Travel Med Infect Dis* **2020**.
- 287 10. Kirby T. South America prepares for the impact of COVID-19. *The Lancet Respiratory*
288 *Medicine* **2020**; online first.
- 289 11. World Bank. The Economy in the Time of CoVID-19. Available from:
290 <https://bit.ly/35B2r3y>. Accessed April 2020.
- 291 12. Ministry of Health. Cifras Oficiales COVID-19. Available from:
292 <https://www.gob.cl/coronavirus/cifrasoficiales/>. Accessed May 22 2020.

- 293 13. Ministry of Health. Dispone medidas sanitarias que indica por brote de COVID-19.
294 Norms 1143498, 1143591, 1746958, 1143651 Available from:
295 <https://www.leychile.cl/N?i=1143498&f=2020-04-04&p=>.
- 296 14. Ministry of Health. Dispone régimen especial de cumplimiento de jornada laboral y
297 flexibilidad horaria por brote de coronavirus (COVID-19). Norm 1143629. Available from:
298 <https://www.leychile.cl/N?i=1143629&f=2020-03-20&p=>.
- 299 15. Ministerio del Interior y Seguridad Pública. Declara estado de excepción constitucional
300 de catástrofe, por calamidad pública, en el territorio, norma 1143580 decreto108. Available
301 from: <https://www.leychile.cl/N?i=1143580&f=2020-03-26&p=>.
- 302 16. Tariq A, Undurraga EA, Laborde CC, et al. Early transmission dynamics of COVID-19 in
303 Chile: From sub-exponential ascending growth dynamics to a stationary disease wave,
304 March-April, 2020. medRxiv **2020**:2020.05.15.20103069.
- 305 17. McGowan C. Chile doctors fear complacency over Covid-19 after initial successes. The
306 Guardian. Santiago de Chile, **2020**.
- 307 18. Rainisch G, Undurraga EA, Chowell G. A dynamic modeling tool for estimating
308 healthcare demand from the COVID19 epidemic and evaluating population-wide
309 interventions. Int J Infect Dis **2020**.
- 310 19. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
311 China. N Engl J Med **2020**.
- 312 20. Cao J, Hu X, Cheng W, Yu L, Tu W-J, Liu Q. Clinical features and short-term outcomes
313 of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Medicine
314 **2020**:1-3.

- 315 21. Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the
316 transmission dynamics in Wuhan, China. *Nat Med* **2020**.
- 317 22. Reed C, Biggerstaff M, Finelli L, et al. Novel framework for assessing epidemiologic
318 effects of influenza epidemics and pandemics. *Emerg Infect Dis* **2013**; 19:85.
- 319 23. Mizumoto K, Chowell G. Estimating risk for death from 2019 novel coronavirus disease,
320 China, January-February 2020. *Emerg Infect Dis* **2020**; 26:10-3201.
- 321 24. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid
322 dissemination of novel coronavirus (COVID-19). *Science* **2020**; 368:489-93.
- 323 25. Riou J, Hauser A, Counotte MJ, Althaus CL. Adjusted age-specific case fatality ratio
324 during the COVID-19 epidemic in Hubei, China, January and February 2020. *medRxiv* **2020**.
- 325 26. Ghani AC, Donnelly CA, Cox DR, et al. Methods for Estimating the Case Fatality Ratio
326 for a Novel, Emerging Infectious Disease. *Am J Epidemiol* **2005**; 162:479-86.
- 327 27. Jewell NP, Lei X, Ghani AC, et al. Nonn-parametric estimation of the case fatality ratio
328 with competing risks data: an application to Severe Acute Respiratory Syndrome (SARS).
329 *Statistics in medicine* **2007**; 26:1982-98.
- 330 28. Lipsitch M, Donnelly CA, Fraser C, et al. Potential biases in estimating absolute and
331 relative case-fatality risks during outbreaks. *PLoS Negl Trop Dis* **2015**; 9.
- 332 29. Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden
333 of dengue in Southeast Asia: A systematic analysis. *PLoS Negl Trop Dis* **2013**; 7:e2056.
- 334 30. Wang C, Liu L, Hao X, et al. Evolving Epidemiology and Impact of Non-pharmaceutical
335 Interventions on the Outbreak of Coronavirus Disease 2019 in Wuhan, China. *medRxiv* **2020**.

- 336 31. Jung S-m, Akhmetzhanov AR, Hayashi K, et al. Real-time estimation of the risk of death
337 from novel coronavirus (COVID-19) infection: inference using exported cases. Journal of
338 clinical medicine **2020**; 9:523.
- 339 32. Thomson E, Sanders P. Prognosis. Chile Charts New Path With Rolling Lockdowns,
340 Immunity Cards. Available from: [https://www.bloomberg.com/news/articles/2020-04-](https://www.bloomberg.com/news/articles/2020-04-22/with-immunity-cards-and-rolling-lockdowns-chile-forges-own-path)
341 [22/with-immunity-cards-and-rolling-lockdowns-chile-forges-own-path](https://www.bloomberg.com/news/articles/2020-04-22/with-immunity-cards-and-rolling-lockdowns-chile-forges-own-path). Accessed May 18
342 2020.
- 343 33. Hasell J, Ortiz-Ospina E, Mathieu E, Ritchie H, Roser M. To understand the global
344 pandemic, we need global testing – the Our World in Data COVID-19 Testing dataset.
345 Available from: <https://bit.ly/2ROHdts>. Accessed May 18 2020.
- 346 34. Sociedad Chilena de Medicina Intensiva SOCHIMI. Encuesta nacional sobre ocupación
347 de unidades críticas durante contingencia CoVID-19. Available from: [https://medicina-](https://medicina-intensiva.cl/site/covid/img/noticias/informe_22MY2020.pdf)
348 [intensiva.cl/site/covid/img/noticias/informe_22MY2020.pdf](https://medicina-intensiva.cl/site/covid/img/noticias/informe_22MY2020.pdf). Accessed May 22 2020.
- 349 35. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
350 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess
351 cruise ship, Yokohama, Japan, 2020. Eurosurveillance **2020**; 25:2000180.
- 352 36. Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JA. Early epidemiological
353 assessment of the virulence of emerging infectious diseases: a case study of an influenza
354 pandemic. PLoS One **2009**; 4.
- 355 37. Tsuzuki S, Lee H, Miura F, et al. Dynamics of the pneumonic plague epidemic in
356 Madagascar, August to October 2017. Eurosurveillance **2017**; 22.

- 357 38. Gamerman D, Lopes HF. Markov chain Monte Carlo: stochastic simulation for Bayesian
358 inference. CRC Press, **2006**.
- 359 39. Gelman A, Rubin DB. Inference from iterative simulation using multiple sequences. *Stat*
360 *Sci* **1992**; 7:457-72.
- 361 40. Feng Z, Li Q, Zhang Y, et al. The epidemiological characteristics of an outbreak of 2019
362 novel coronavirus diseases (COVID-19)-China, 2020. *China CDC Weekly* **2020**; 2:113-22.
- 363 41. Dowd JB, Andriano L, Brazel DM, et al. Demographic science aids in understanding the
364 spread and fatality rates of COVID-19. *Proc Natl Acad Sci* **2020**; 117:9696-8.
- 365 42. Mizumoto K, Chowell G, Simonsen L, Nishiura H. The burden of influenza and
366 respiratory syncytial viruses in Japan, 2006–2014: A region-and age-specific excess mortality
367 study. *Int J Infect Dis* **2019**; 79:96-7.
- 368 43. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
369 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **2020**; 395:1054-62.
- 370 44. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with
371 COVID-19: evidence from meta-analysis. *Aging* **2020**; 12:6049-57.
- 372 45. Sistema Nacional de Información Municipal. Datos Municipales. Available from:
373 http://datos.sinim.gov.cl/datos_municipales.php. Accessed May 19 2020.
- 374 46. Cociña M, Frei R, Larrañaga O. Desiguales: Orígenes, cambios y desafíos de la brecha
375 social en Chile. Programa de las Naciones Unidas para el Desarrollo (PNUD), **2017**.

- 376 47. Asahi K, Undurraga EA, Wagner R. Benchmarking the CoVID-19 pandemic across
377 countries and states in the U.S.A. under heterogeneous testing. medRxiv
378 **2020**:2020.05.01.20087882.
- 379 48. Instituto Nacional de Estadísticas. Estimaciones y proyecciones de la población de Chile
380 1992-2050. Available from: <https://www.censo2017.cl/>. Accessed April 2 2020.
- 381 49. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities,
382 and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area.
383 *Jama* **2020**.
- 384 50. Epidemiology Working Group for NCIP Epidemic Response. The epidemiological
385 characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.
386 *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi* **2020**; 41:145.
387
388
389
390
391

392 **Tables**

393

394 **Table 1.** Distribution of the CoVID-19 cases in Chile by sex and age groups, as of May 18,

395 2020

		Confirmed cases (%)	Deaths (%)	Crude fatality rate (%)
	Total	46,048 (100.00)	544 (100.00)	1.18%
Sex	Male	24,523 (53.3)	NA	NA
	Female	21,525 (46.7)	NA	NA
Age-group	0-39	24,830 (53.9)	11 (2.0)	0.04
	40-49	7,953 (17.3)	31 (5.7)	0.39
	50-59	6,624 (14.4)	51 (9.4)	0.77
	60-69	3,748 (8.1)	92 (16.9)	2.45
	70-79	1,785 (3.9)	152 (27.9)	8.52
	80 and above	1,108 (2.4)	207 (38.1)	18.68

396

397

398 **Table 2.** Summary results of time-delay adjusted case fatality ratio of COVID-19 by age
 399 group in Chile, 2020 (May 18, 2020)

Age group	Latest estimate (95% CrI ^a)	Range of median estimates during the study period	Crude CFR (95% CI ^b)
0-39	0.08% (0.04-0.13%)	0.08-0.25%	0.00% (0.00-0.10%) 10/24830
40-49	0.61% (0.41-0.87%)	0.19-0.61%	0.40% (0.20-0.50%) 28/7953
50-59	1.06% (0.76-1.40%)	0.49-1.35%	0.60% (0.40-0.80%) 40/6624
60-69	3.79% (3.04-4.66%)	3.42-4.99%	2.20% (1.70-2.70%) 82/3748
70-79	12.22% (10.40-14.38%)	11.07-21.19%	7.50% (6.30-8.80%) 133/1785
80-	26.27% (22.95-29.80)	25.23-68.95%	16.70% (14.50-19.00%) 185/1108
All age groups	1.78% (1.63-1.95%)	1.72-2.56%	1.00% (0.90-1.10%) 478/46048

400 **Notes.**

401 ^aCrI: 95% credibility intervals (CrI)


402 ^b95%CI: 95% confidence interval

403 **Figures**

404

405 **Figure 1.** Gender proportion of reported COVID-19 cases by age groups (A), and cumulative


406 morbidity ratio by gender and age group (B), March through May 18th, 2020, Chile



407

408

409 **Figure 2:** Temporal distribution of cases and deaths by age group due to COVID-19, March through May 18th, 2020, Chile.



410


411 **Notes**

412 Cumulative cases of CoVID-19 by the following age groups (A) 0-39, (B) 40-49, (C) 50-59, (D) 60-69, (E) 70-79, (F) 80years or more , (G) all cases and cumulative deaths

413 by age group (H) 0-39, (I) 40-49, (J) 50-59, (K) 60-69, (L) 70-79, (M) 80 years or more, (N) all fatal cases over time. Day 1 corresponds to April 1st in 2020. As the dates of

414 illness onset were not available, we used dates of reporting.

415 **Figure 3:** Temporal variation of risk of death caused by COVID-19, March through May 18th, 2020, Chile.




416
417

Notes.

418 Observed and posterior estimated of crude case fatality ratio of persons aged (A) 0-39, (B) 40-49, (C) 50-59, (D) 60-69, (E) 70-79, (F) 80 and more, and (G) all age groups.
 419 Time-delay adjusted case fatality ratio of persons aged (H) 0-39, (I) 40-49, (J) 50-59, (K) 60-69, (L) 70-79, (M) 80 and more, and (N) all age groups. Day 1 corresponds to
 420 April 1st, 2020. Black dots show crude case fatality ratio, and light and dark indicates 95% and 50% credible intervals for posterior estimates, respectively.

421 **Figure 4.** Latest estimates of time-delay adjusted risk of death caused by COVID-19 by age
422 group, March-May 2020, Chile.



423

424 **Notes**

425 Distribution of time-delay adjusted case fatality risks derived from the latest estimates (May 8, 2020) are
426 presented. Top to bottom: aged 0-39, aged 40-49, aged 50-59, aged 60-69, aged 70-79, aged 80- and all age
427 groups.

428

429